Nerviano Medical Sciences S.r.l. Announces Clinical Data on NMS-03592088 selected for Oral Presentation at AACR Annual Meeting 2023
April 4, 2023

NERVIANO, 4 April 2023 – Nerviano Medical Sciences Srl (Company), a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, today announced that data from the  Phase I/II clinical study of NMS-03592088 in Acute Myeloid Leukemia  will be reported in an oral presentation by Dr. Antonio Curti, MD, PhD,  IRCCS Azienda Ospedaliero-Universitaria di Bologna, at the upcoming AACR Annual Meeting which will be held April 14 – 19, Orange County Convention Center, Orlando, Florida.

Details of the upcoming oral presentation are as follows:

Title:  NMS-03592088, a novel, potent FLT3, KIT and CSF1R inhibitor with activity in FLT3 positive acute myeloid leukemia patients with prior FLT3 inhibitor experience
Presenter: Dr. Antonio Curti, Istituto di Ematologia Seràgnoli, IRCCS Azienda Ospedaliero-Universitaria di Bologna
Session: CTMS01 – Novel Clinical Trials for Hematological Malignancies- CT025
Session Date/Time: April 16, 2023, 4:05 PM – 4:15 PM
Location: Valencia A – Convention Center

The data are embargoed until the day of the presentation. A copy of the oral presentation will be available at following presentation at the meeting.
– – – – – – – – – – – –

About NMS-03592088

Acute Myeloid Leukemia (AML) is a rapidly progressing hematologic malignancy that most frequently develops in older adults. FLT3 mutations occur in approximately 30% of AML patients and are associated with aggressive disease, higher relapse rates and worse survival. Despite the approval of FLT3 inhibitors midostaurin and gilteritinib that improve the treatment of FLT3 positive patients, the prognosis of patients with relapsed or refractory disease is poor.

NMS-03592088 is a novel, potent inhibitor of FLT3, KIT and CSF1R, all relevant targets in AML. NMS-03592088 showed superior preclinical activity compared with approved FLT3 inhibitors in different FLT3-driven models. In addition, NMS-03592088 is active on FLT3 gatekeeper mutation F691L causing resistance to first generation FLT3 inhibitors.

MKIA-088-001 is a Phase I/II study of NMS-03592088 administered as single agent in relapsed or refractory AML and CMML patients. The trial is currently open for enrollment.

Link: NMS-088_AACR2023_First press release


Welcome and Check out our new motion picture!